EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis

Yasutaka Yamauchi, Mitsuyoshi Takahara, Yoshimitsu Soga, Osamu Iida, Akiko Tanaka, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Amane Kozuki, Akira Miyamoto, POPCORN Investigators

JACC: Cardiovascular Interventions · 2025-07 · 18 (13) · 1660-1670

DOI: 10.1016/j.jcin.2025.05.001 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-07. Verfasst von Yasutaka Yamauchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Takatsu General Hospital, Kawasaki, Japan. Electronic address: qqfw76rd@bell.ocn.ne.jp. Hauptthemen laut MEDLINE: Renal Dialysis, Popliteal Artery, Vascular Patency, Femoral Artery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Drug-coated balloons (DCBs) are widely used as a core treatment for femoropopliteal lesions, but no largescale prospective studies have evaluated DCB in hemodialysis (HD) patients. OBJECTIVES: The authors sought to clarify restenosis risk and associated factors after DCB therapy for symptomatic femoropopliteal artery disease in patients on HD. METHODS: We analyzed the database of a multicenter prospective study that registered patients undergoing DCB treatment (either Lutonix or IN.PACT Admiral) from March 2018 to December 2019. Of the 3,165 registered lesions, 991 lesions were in patients on HD. The primary outcome was freedom from restenosis. RESULTS: The HD group was younger (72 ± 9 years vs 76 ± 9 years) and had a higher frequency of diabetes (76.5% [557/728 patients]) vs 60.8% [1,081/1,779 patients]). The prevalence of chronic limb-threatening ischemia was 52.2% (444/850 patients) vs 22.1% (437/1,977 patients). Lutonix was used in 30.6% (688/991 lesions) vs 21.3% (462/2,174 lesions), and IN.PACT Admiral was used in 69.4% (303/991 lesions) vs 78.7% (1,712/2,174 lesions). After propensity-score matching, the 1- and 3-year rates of freedom from restenosis in the HD and non-HD groups were 82.2% (95% CI: 79.0%-85.3%) vs 85.8% (83.0%-88.7%) at 1 year and 61.9% (57.7%-66.1%) vs 66.3% (62.2%-70.4%) at 3 years, respectively. In the HD group, restenosis occurred in 363 lesions during a median follow-up of 16.2 months (Q1-Q3: 7.2-35.5 months). Factors independently associated with restenosis risk in the HD group were no below-the-knee runoff, history of endovascular therapy, popliteal lesion, severe calcification, use of Lutonix, and severe dissection. CONCLUSIONS: DCB endovascular therapy is a reasonable treatment for femoropopliteal lesions in patients on HD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisPopliteal ArteryVascular PatencyFemoral ArteryPeripheral Arterial DiseaseAngioplasty, BalloonCoated Materials, BiocompatibleVascular Access DevicesCardiovascular AgentsHumansMaleFemaleAgedTime FactorsRisk FactorsMiddle AgedAged, 80 and overTreatment OutcomeDatabases, FactualRecurrenceRisk AssessmentProspective StudiesEquipment DesignRegistries

Stichwörter der Autor:innen

drug-coated balloonendovascular therapyfemoropopliteal diseasehemodialysislower extremity artery diseasepatency

Substanzen

Coated Materials, BiocompatibleCardiovascular Agents

Autor:innen und Institutionen

  • Cardiovascular Center, Takatsu General Hospital, Kawasaki, Japan. Electronic address: qqfw76rd@bell.ocn.ne.jp.
  • Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
  • Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.
  • Cardiovascular Center, Sendai Kousei Hospital, Sendai, Japan.
  • Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.

Zitieren

APA

Yamauchi, Y., Takahara, M., Soga, Y., Iida, O., Tanaka, A., Tobita, K., Kawasaki, D., Fujihara, M., Kozuki, A., Miyamoto, A., & POPCORN Investigators (2025). Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis. JACC: Cardiovascular Interventions, 18(13), 1660-1670. https://doi.org/10.1016/j.jcin.2025.05.001

Vancouver

Yamauchi Y, Takahara M, Soga Y, Iida O, Tanaka A, Tobita K, et al. Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis. JACC: Cardiovascular Interventions. 2025;18(13):1660-1670. doi:10.1016/j.jcin.2025.05.001

BibTeX
@article{Yamauchi2025,
  author = {Yamauchi, Yasutaka and Takahara, Mitsuyoshi and Soga, Yoshimitsu and Iida, Osamu and Tanaka, Akiko and Tobita, Kazuki and Kawasaki, Daizo and Fujihara, Masahiko and Kozuki, Amane and Miyamoto, Akira and POPCORN Investigators, POPCORN Investigators},
  title = {Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {13},
  pages = {1660--1670},
  doi = {10.1016/j.jcin.2025.05.001}
}
Kostenlos starten →